Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of 14.80% - By PMI
February 15, 2024 17:02 ET
|
PMI
Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...
Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma, Novartis, Roche, Biohaven Pharmaceuticals, Scholar Rock, AnnJi Pharmaceutical
October 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma,...
Insights on the Spinal Muscular Atrophy Global Market to 2027 - Featuring AveXis, Biogen and Cytokinetics Among Others
April 07, 2021 07:28 ET
|
Research and Markets
Dublin, April 07, 2021 (GLOBE NEWSWIRE) -- The "Spinal Muscular Atrophy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Amid the COVID-19...
Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S
October 20, 2015 15:37 ET
|
Transparency Market Research
Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research Spinal Muscular Atrophy Market: Pipeline Assessment, Size, Growth,...